{"url_path":"/sec/fbiop/10-q/2026/item-3","section_key":"item-3","section_title":"Item 3 Defaults Upon Senior Securities","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1429260/0001104659-26-061233-index.html","accession_number":"0001104659-26-061233","cik":"0001429260","ticker":"FBIO","issuer_name":"Fortress Biotech, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1429260/0001104659-26-061233-index.html","primary_entity_key":"0001429260","primary_entity_name":"Fortress Biotech, Inc."},"word_count":170,"has_tables":true,"body_markdown":"Item 3.      Defaults Upon Senior Securities\n\nOn July 5, 2024, Fortress announced that the Company’s Board of Directors had decided to pause the monthly dividend of $0.1953125 per share of the Company’s Series A Preferred Stock. In accordance with the terms of the Series A Preferred Stock, dividends on the Series A Preferred Stock will continue to accrue and cumulate until such dividends are authorized or declared. The pausing of these dividends will defer approximately $0.7 million in cash dividend payments each month. The Board intends to revisit its decision regarding the monthly dividend regularly and will assess the profitability and cash flow of the Company to determine whether and when the pause should be lifted.\n\n​\n\n87\n\n[Table of Contents](#TOC)\n\nDuring the three months ended March 31, 2026, no dividends were declared by the Board of Directors. At March 31, 2026, the Company had total undeclared dividends of approximately $14.0 million, which represents the cumulated (but undeclared) dividends due to Series A Preferred shareholders on March 31, 2026.\n\n​"}